CN111617212A - 一种治疗皮肤病的中药组合物 - Google Patents
一种治疗皮肤病的中药组合物 Download PDFInfo
- Publication number
- CN111617212A CN111617212A CN202010585567.5A CN202010585567A CN111617212A CN 111617212 A CN111617212 A CN 111617212A CN 202010585567 A CN202010585567 A CN 202010585567A CN 111617212 A CN111617212 A CN 111617212A
- Authority
- CN
- China
- Prior art keywords
- parts
- traditional chinese
- chinese medicine
- medicine composition
- realgar
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 65
- 208000017520 skin disease Diseases 0.000 title claims abstract description 20
- 239000003814 drug Substances 0.000 claims abstract description 59
- 229910052957 realgar Inorganic materials 0.000 claims abstract description 23
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical compound C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 claims abstract description 21
- 239000000843 powder Substances 0.000 claims abstract description 21
- 239000004575 stone Substances 0.000 claims abstract description 21
- REPVLJRCJUVQFA-UHFFFAOYSA-N (-)-isopinocampheol Natural products C1C(O)C(C)C2C(C)(C)C1C2 REPVLJRCJUVQFA-UHFFFAOYSA-N 0.000 claims abstract description 19
- 229940116229 borneol Drugs 0.000 claims abstract description 19
- CKDOCTFBFTVPSN-UHFFFAOYSA-N borneol Natural products C1CC2(C)C(C)CC1C2(C)C CKDOCTFBFTVPSN-UHFFFAOYSA-N 0.000 claims abstract description 19
- DTGKSKDOIYIVQL-UHFFFAOYSA-N dl-isoborneol Natural products C1CC2(C)C(O)CC1C2(C)C DTGKSKDOIYIVQL-UHFFFAOYSA-N 0.000 claims abstract description 19
- 238000002156 mixing Methods 0.000 claims abstract description 18
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 10
- 229940057995 liquid paraffin Drugs 0.000 claims abstract description 9
- 229940099259 vaseline Drugs 0.000 claims abstract description 9
- 239000002994 raw material Substances 0.000 claims abstract description 7
- 238000002791 soaking Methods 0.000 claims abstract description 5
- 238000005520 cutting process Methods 0.000 claims abstract description 4
- 238000005303 weighing Methods 0.000 claims abstract description 4
- 240000004534 Scutellaria baicalensis Species 0.000 claims description 19
- 235000017089 Scutellaria baicalensis Nutrition 0.000 claims description 19
- 241000205585 Aquilegia canadensis Species 0.000 claims description 18
- 240000009138 Curcuma zedoaria Species 0.000 claims description 18
- 241000304195 Salvia miltiorrhiza Species 0.000 claims description 18
- 235000011135 Salvia miltiorrhiza Nutrition 0.000 claims description 18
- 239000007788 liquid Substances 0.000 claims description 15
- 241000241550 Cyathula Species 0.000 claims description 10
- 244000116484 Inula helenium Species 0.000 claims description 10
- 235000002598 Inula helenium Nutrition 0.000 claims description 10
- 238000002360 preparation method Methods 0.000 claims description 9
- 230000001954 sterilising effect Effects 0.000 claims description 9
- 239000004166 Lanolin Substances 0.000 claims description 8
- 229940039717 lanolin Drugs 0.000 claims description 8
- 235000019388 lanolin Nutrition 0.000 claims description 8
- 239000002674 ointment Substances 0.000 claims description 8
- 239000006228 supernatant Substances 0.000 claims description 8
- 244000272264 Saussurea lappa Species 0.000 claims description 4
- 235000006784 Saussurea lappa Nutrition 0.000 claims description 4
- 238000001816 cooling Methods 0.000 claims description 3
- 238000001914 filtration Methods 0.000 claims description 3
- 238000010438 heat treatment Methods 0.000 claims description 3
- 238000002844 melting Methods 0.000 claims description 3
- 230000008018 melting Effects 0.000 claims description 3
- 239000000463 material Substances 0.000 claims description 2
- 238000001556 precipitation Methods 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 17
- 229940126680 traditional chinese medicines Drugs 0.000 abstract description 3
- 208000015181 infectious disease Diseases 0.000 abstract description 2
- 230000009467 reduction Effects 0.000 abstract description 2
- 241000628997 Flos Species 0.000 abstract 1
- 201000004624 Dermatitis Diseases 0.000 description 10
- 230000002401 inhibitory effect Effects 0.000 description 10
- 208000010668 atopic eczema Diseases 0.000 description 8
- 206010063409 Acarodermatitis Diseases 0.000 description 6
- 241000193830 Bacillus <bacterium> Species 0.000 description 6
- 201000004681 Psoriasis Diseases 0.000 description 6
- 241000447727 Scabies Species 0.000 description 6
- 230000000052 comparative effect Effects 0.000 description 6
- 208000005687 scabies Diseases 0.000 description 6
- 208000002874 Acne Vulgaris Diseases 0.000 description 5
- 241000191967 Staphylococcus aureus Species 0.000 description 5
- 206010000496 acne Diseases 0.000 description 5
- -1 diterpene quinone compounds Chemical class 0.000 description 5
- 201000010582 ecthyma Diseases 0.000 description 5
- 208000004396 mastitis Diseases 0.000 description 5
- 210000003491 skin Anatomy 0.000 description 5
- 240000000774 Cunila origanoides Species 0.000 description 4
- 235000018274 Cunila origanoides Nutrition 0.000 description 4
- 235000014866 Dictamnus albus Nutrition 0.000 description 4
- 206010061218 Inflammation Diseases 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 230000004054 inflammatory process Effects 0.000 description 4
- 206010020751 Hypersensitivity Diseases 0.000 description 3
- 206010040943 Skin Ulcer Diseases 0.000 description 3
- 241000607626 Vibrio cholerae Species 0.000 description 3
- 244000052616 bacterial pathogen Species 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 229920001282 polysaccharide Polymers 0.000 description 3
- 239000005017 polysaccharide Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 229940118696 vibrio cholerae Drugs 0.000 description 3
- 239000000341 volatile oil Substances 0.000 description 3
- 241001480043 Arthrodermataceae Species 0.000 description 2
- 201000001320 Atherosclerosis Diseases 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- WIONIXOBNMDJFJ-UHFFFAOYSA-N Dictamnine Chemical compound C1=CC=C2C(OC)=C(C=CO3)C3=NC2=C1 WIONIXOBNMDJFJ-UHFFFAOYSA-N 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 2
- WWNNZCOKKKDOPX-UHFFFAOYSA-N N-methylnicotinate Chemical compound C[N+]1=CC=CC(C([O-])=O)=C1 WWNNZCOKKKDOPX-UHFFFAOYSA-N 0.000 description 2
- 208000003251 Pruritus Diseases 0.000 description 2
- 206010037660 Pyrexia Diseases 0.000 description 2
- 241000191940 Staphylococcus Species 0.000 description 2
- 241000194017 Streptococcus Species 0.000 description 2
- 241000223238 Trichophyton Species 0.000 description 2
- 208000026935 allergic disease Diseases 0.000 description 2
- 230000007815 allergy Effects 0.000 description 2
- 230000000202 analgesic effect Effects 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 239000003146 anticoagulant agent Substances 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000037304 dermatophytes Effects 0.000 description 2
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 229930003935 flavonoid Natural products 0.000 description 2
- 235000017173 flavonoids Nutrition 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 2
- 229960000367 inositol Drugs 0.000 description 2
- 244000000010 microbial pathogen Species 0.000 description 2
- 230000004089 microcirculation Effects 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 150000007965 phenolic acids Chemical class 0.000 description 2
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 229930182490 saponin Natural products 0.000 description 2
- 150000007949 saponins Chemical class 0.000 description 2
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 2
- 231100000019 skin ulcer Toxicity 0.000 description 2
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 2
- 231100000167 toxic agent Toxicity 0.000 description 2
- 239000003440 toxic substance Substances 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- 231100000765 toxin Toxicity 0.000 description 2
- DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical compound C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 description 1
- XVFMTWMMWSPTEU-UHFFFAOYSA-N 2,3-dihydroxy-6-methylbenzoic acid Chemical compound CC1=CC=C(O)C(O)=C1C(O)=O XVFMTWMMWSPTEU-UHFFFAOYSA-N 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 241000208838 Asteraceae Species 0.000 description 1
- 244000063299 Bacillus subtilis Species 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 240000000572 Blumea balsamifera Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 206010007247 Carbuncle Diseases 0.000 description 1
- 241000723346 Cinnamomum camphora Species 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 235000003405 Curcuma zedoaria Nutrition 0.000 description 1
- 206010012504 Dermatophytosis Diseases 0.000 description 1
- 206010048768 Dermatosis Diseases 0.000 description 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 206010017533 Fungal infection Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
- 208000006877 Insect Bites and Stings Diseases 0.000 description 1
- 229920001202 Inulin Polymers 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- 241000218195 Lauraceae Species 0.000 description 1
- 208000005230 Leg Ulcer Diseases 0.000 description 1
- 241000589902 Leptospira Species 0.000 description 1
- 241001460074 Microsporum distortum Species 0.000 description 1
- 241000187480 Mycobacterium smegmatis Species 0.000 description 1
- 241000187479 Mycobacterium tuberculosis Species 0.000 description 1
- 208000031888 Mycoses Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010054107 Nodule Diseases 0.000 description 1
- IPQKDIRUZHOIOM-UHFFFAOYSA-N Oroxin A Natural products OC1C(O)C(O)C(CO)OC1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC=CC=1)O2 IPQKDIRUZHOIOM-UHFFFAOYSA-N 0.000 description 1
- 206010033733 Papule Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 241000588769 Proteus <enterobacteria> Species 0.000 description 1
- 206010037888 Rash pustular Diseases 0.000 description 1
- 241001093501 Rutaceae Species 0.000 description 1
- 241000293871 Salmonella enterica subsp. enterica serovar Typhi Species 0.000 description 1
- 241000607762 Shigella flexneri Species 0.000 description 1
- 241000191963 Staphylococcus epidermidis Species 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- 208000033809 Suppuration Diseases 0.000 description 1
- 208000002474 Tinea Diseases 0.000 description 1
- 241000893963 Trichophyton concentricum Species 0.000 description 1
- 241001480050 Trichophyton violaceum Species 0.000 description 1
- 208000037386 Typhoid Diseases 0.000 description 1
- FHKPLLOSJHHKNU-INIZCTEOSA-N [(3S)-3-[8-(1-ethyl-5-methylpyrazol-4-yl)-9-methylpurin-6-yl]oxypyrrolidin-1-yl]-(oxan-4-yl)methanone Chemical compound C(C)N1N=CC(=C1C)C=1N(C2=NC=NC(=C2N=1)O[C@@H]1CN(CC1)C(=O)C1CCOCC1)C FHKPLLOSJHHKNU-INIZCTEOSA-N 0.000 description 1
- 206010000269 abscess Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 208000030961 allergic reaction Diseases 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000702 anti-platelet effect Effects 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 230000002785 anti-thrombosis Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 229910052785 arsenic Inorganic materials 0.000 description 1
- RQNWIZPPADIBDY-UHFFFAOYSA-N arsenic atom Chemical compound [As] RQNWIZPPADIBDY-UHFFFAOYSA-N 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- IKIIZLYTISPENI-ZFORQUDYSA-N baicalin Chemical compound O1[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC=CC=1)O2 IKIIZLYTISPENI-ZFORQUDYSA-N 0.000 description 1
- 229960003321 baicalin Drugs 0.000 description 1
- AQHDANHUMGXSJZ-UHFFFAOYSA-N baicalin Natural products OC1C(O)C(C(O)CO)OC1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC=CC=1)O2 AQHDANHUMGXSJZ-UHFFFAOYSA-N 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000001914 calming effect Effects 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000013043 chemical agent Substances 0.000 description 1
- 239000002561 chemical irritant Substances 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 239000001812 curcuma zedoaria berg. rosc. Substances 0.000 description 1
- 235000012754 curcumin Nutrition 0.000 description 1
- 229940109262 curcumin Drugs 0.000 description 1
- 239000004148 curcumin Substances 0.000 description 1
- 208000031513 cyst Diseases 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- VFLDPWHFBUODDF-UHFFFAOYSA-N diferuloylmethane Natural products C1=C(O)C(OC)=CC(C=CC(=O)CC(=O)C=CC=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-UHFFFAOYSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 229930004069 diterpene Natural products 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 244000053095 fungal pathogen Species 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000002949 hemolytic effect Effects 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229940029339 inulin Drugs 0.000 description 1
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 230000006651 lactation Effects 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 229920005610 lignin Chemical class 0.000 description 1
- 230000003859 lipid peroxidation Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- 201000007227 lymph node tuberculosis Diseases 0.000 description 1
- 201000004792 malaria Diseases 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 210000002445 nipple Anatomy 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 235000009048 phenolic acids Nutrition 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 208000005069 pulmonary fibrosis Diseases 0.000 description 1
- 208000029561 pustule Diseases 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000001603 reducing effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 201000003068 rheumatic fever Diseases 0.000 description 1
- 230000037380 skin damage Effects 0.000 description 1
- 238000001256 steam distillation Methods 0.000 description 1
- 150000005856 steroid saponins Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 229910052569 sulfide mineral Inorganic materials 0.000 description 1
- 235000018553 tannin Nutrition 0.000 description 1
- 239000001648 tannin Substances 0.000 description 1
- 229920001864 tannin Polymers 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 201000008297 typhoid fever Diseases 0.000 description 1
- 241000712461 unidentified influenza virus Species 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 210000003556 vascular endothelial cell Anatomy 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 235000019509 white turmeric Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/539—Scutellaria (skullcap)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
- A61K33/12—Magnesium silicate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/36—Arsenic; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/21—Amaranthaceae (Amaranth family), e.g. pigweed, rockwort or globe amaranth
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/285—Aucklandia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/35—Caprifoliaceae (Honeysuckle family)
- A61K36/355—Lonicera (honeysuckle)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/537—Salvia (sage)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8964—Anemarrhena
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9066—Curcuma, e.g. common turmeric, East Indian arrowroot or mango ginger
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/14—Ectoparasiticides, e.g. scabicides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Alternative & Traditional Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Inorganic Chemistry (AREA)
- Gynecology & Obstetrics (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pulmonology (AREA)
- Pregnancy & Childbirth (AREA)
- Neurosurgery (AREA)
- Tropical Medicine & Parasitology (AREA)
- Molecular Biology (AREA)
- Toxicology (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明提供一种治疗皮肤病的中药组合物,涉及中医药技术领域,该中药组合物包括以下成分:黄芩、丹参、白藓皮、川牛膝、莪术、银花、木香、知母、雄黄、冰片、医用石粉;按配方称取原料,将原料切碎混合后冷水浸泡,浸泡后小火煎煮,取上清液继续煎煮浓缩得到的稠膏状物A,向其中添加雄黄、冰片和医药石粉混合均匀,最后与凡士林、羊毛脂和液体石蜡混合得中药组成物;通过本发明制作的中药组成物具有疗效显著、复发情况少、使用方便以及减少相关感染的优点。
Description
技术领域
本发明涉及中医药技术领域,具体涉及一种治疗皮肤病的中药组合物。
背景技术
牛皮癣是一种常见的具有特征性皮损的慢性易于复发的炎症性皮肤病。研究证实链球菌感染、金黄色葡萄球菌感染、真菌感染与银屑病的发病有关;乳腺炎由哺乳经验不足或方法不当所致,致病菌多为金黄色葡萄球菌,少数为溶血性链球菌,通过乳头皮肤破损或输乳管侵入乳腺实质,大量繁殖破坏乳腺组织,形成多房性脓肿;臁疮腿是因气血耗伤,脉络不通畅,局部气血运行失常,再加上损伤,湿热、虫咬以及湿疹等因素所致;痤疮主要与皮脂分泌过多、毛囊皮脂腺导管堵塞、细菌感染和炎症反应等因素密切相关,表现为炎性丘疹、脓疱、结节和囊肿;湿疹是一种常见的由多种内外因素引起的表皮及真皮浅层的炎症性皮肤病,一般认为与变态反应有一定关系,代表皮肤对于化学制剂、蛋白、细菌与真菌等种种物质的变应性反应。
这些皮肤病治疗需要复发性专用药,目前市场上中成药没有疗效比较出色的产品,治疗适应症不明确,效果也不佳,易反复发作。
发明内容
(一)解决的技术问题
针对现有技术的不足,本发明提供了一种治疗皮肤病的中药组合物,通过黄芩、丹参、白藓皮、川牛膝、莪术、银花、木香、知母、雄黄、冰片、医用石粉复配制成中药组合物膏剂,该中药组合物膏剂对牛皮癣、红斑狼疮、淋巴结核、乳腺炎、臁疮腿、痤疮、湿疹、疱疹、羊疹、疥疮及各种毒疮皮肤病等都有疗效。
(二)技术方案
为实现以上目的,本发明通过以下技术方案予以实现:
一种治疗皮肤病的中药组合物,该中药组合物包括如下重量份的组分:黄芩5-10份、丹参5-10份、白藓皮8-12份、川牛膝4-8份、莪术6-14份、银花6-14份、木香4-12份、知母4-12份、雄黄4-12份、冰片6-14份、医用石粉10-16份。
进一步地,该中药组合物包括如下重量份的组分:黄芩6-9份、丹参6-9份、白藓皮9-11份、川牛膝4-6份、莪术8-12份、银花8-12份、木香5-7份、知母5-7份、雄黄5-7份、冰片8-12份、医用石粉12-14 份。
进一步地,该中药组合物包括如下重量份的组分:黄芩7份、丹参7份、白藓皮9份、川牛膝5份、莪术10份、银花10份、木香6 份、知母6份、雄黄6份、冰片10份、医用石粉13份。
进一步地,该中药组合物为软膏剂,还含有如下重量份数的成分:凡士林40-60份、液体石蜡4-6份、羊毛脂4-6份。
进一步地,中药组合物的制作方法为:
(1)按上述中药组合物的配方称取原料,将黄芩、丹参、白藓皮、川牛膝、莪术、银花、木香、知母切碎后混合得混合料A;
(2)将步骤(1)中混合料A放入砂锅中,冷水浸泡18-24小时;
(3)将步骤(2)中砂锅放置在小火上煮沸3小时,再加适量水煎煮3小时,将药渣过滤去除,得到药液A;将药渣挤压后得到的药液和药液A混合得到药液B;
(4)将步骤(3)得到的药液B静置10-12小时,静置沉淀后取上清液A;
(5)将步骤(4)得到的上清液A加热至沸,撇去浮沫,小火煎煮浓缩,得到稠膏状物A;
(6)向步骤(5)中得到的稠膏状物A中添加雄黄、冰片和医药石粉混合均匀得到混合料B;
(7)将凡士林熔化后,灭菌冷却,将羊毛脂灭菌,将液体石蜡灭菌,将凡士林、羊毛脂和液体石蜡混合得混合料C;
(8)将步骤(6)中得到的混合料B和步骤(7)中得到的混合料 C混合得到软膏,所得软膏即为本发明中药组成物。
进一步地,雄黄研细过100-120目筛、冰片研细过200-230目筛、医用石粉研细过100-120目筛。
进一步地,步骤(2)中冷水没过药材15-20厘米。
进一步地,步骤(4)中所得上清液A过100-120目筛。
(三)有益效果
本发明提供了一种治疗皮肤病的中药组合物,采用黄芩、丹参、白藓皮、川牛膝、莪术、银花、木香、知母、雄黄、冰片、医用石粉制作中药组合物。
黄芩的有效化学成分是黄酮类化合物黄芩苷,具有抗炎、抗病原微生物(抗内毒素)、解热、保肝利胆、镇静等功效;还具有抗免疫反应作用,尤其对1型变态反应(过敏反应)作用显著。
丹参的主要有效成分是脂溶性的二萜醌类化合物和水溶性的酚酸类成分。现代药理研究表明,丹参具有保护血管内皮细胞、抗心律失常、抗动脉粥样硬化、改善微循环、保护心肌、抑制和解除血小板聚集、增加冠脉流量,提高机体耐缺氧能力,抑制胶原纤维的产生和促进纤维蛋白的降解、抗炎、抗脂质过氧化和清除自由基、以及保护肝细胞、抗肺纤维化等作用。丹参在体外对葡萄球菌、霍乱弧菌、结核杆菌、大肠杆菌、变形杆菌、伤寒杆菌、福氏痢疾杆菌都有抑制作用。
白藓皮为芸香科多年生草本植物白藓的皮,含白鲜碱、白鲜内酯、葫芦巴碱、胆碱、秦皮酮、黄柏酮、黄柏酮酸等。用于风热、湿毒所致的湿疮湿疹、皮肤溃烂、脓水淋漓、皮肤瘙痒及湿热黄疸、尿赤、风湿热痹、疥癖、疮癞等。具有解毒和抗真菌作用,对风热、湿毒所致的皮肤病有较可靠的作用。亦可用于急性或慢性黄疸型肝炎、风湿性关节炎。
川牛膝中的化学成分有甾酮、多糖、皂苷等,其成分具有调节血液粘稠度、改善微循环、延缓衰老、抗肿瘤和增强免疫能力等广泛的药理作用。
莪术中的化学成分主要为挥发油和姜黄素类、多糖类、甾醇类、酚酸类、生物碱类等,具有抗肿瘤、抗血小板聚集、抗血栓、调血脂、抗动脉粥样硬化、抗组织纤维化、抗炎镇痛、抗菌抗病毒、降血糖、抗氧化等多种药理学作用。
银花含环己六醇、黄酮类化合物、肌醇、皂苷及鞣质,具有广谱抗菌作用,对黄金色葡萄球菌、疟疾杆菌等多种致病菌均有较强的抑制作用,对钩端螺旋体、流感病毒以及致病霉菌等多种病原微生物亦有抑制作用,此外还具有抗炎解热等作用。
木香主要含有挥发油、木香碱、菊糖等。木香挥发油可抑制链球菌、金黄色葡萄球菌及白色葡萄球菌的生长,对多种致病性皮肤真菌也有抑制作用。
知母中含有大量的甾体皂苷、双苯吡酮类化合物、木质素类化合物、多糖类化合物、有机酸类化合物以及微量元素等。知母煎剂对葡萄球菌、伤寒杆菌、疟疾杆菌、副伤寒杆菌、枯草杆菌、霍乱弧菌有较强的抑制作用。对常见的致病性皮肤藓有抑制作用。
雄黄为硫化物类矿物雄黄族雄黄,主含二硫化二砷,1%浓度对人型、牛型结核杆菌及耻垢杆菌有抑制其生长的作用;雄黄水浸剂(1:2) 在试管内对堇色毛癣菌、同心性毛癣菌、许兰黄癣菌、奥杜盎小芽胞癣菌等皮肤真菌均有不同程度的抑制作用。
冰片是由菊科艾纳香茎叶或樟科植物龙脑樟枝叶经水蒸汽蒸馏并重结晶而得。能抑制猪霍乱弧菌、大肠杆菌、金黄色葡萄球菌的生长。还具有止痛及温和的防腐作用。
医用石粉保护皮肤和粘膜的作用滑石粉由于颗粒小,总面积大,能吸着大量化学刺激物或毒物,因此当撒布于发炎或破损组织的表面时,可有保护的作用。
本发明提供了一种治疗皮肤病的中药组合物,通过黄芩、丹参、白藓皮、川牛膝、莪术、银花、木香、知母、雄黄、冰片、医用石粉制作中药组合物。组方合理,配伍科学,即具有中药清热、解毒、收敛之功效,又具备止痒、抑菌的作用,对牛皮癣、红斑狼疮、淋巴结核、乳腺炎、臁疮腿、痤疮、湿疹、疱疹、羊疹、疥疮及各种毒疮皮肤病等都有疗效,对皮肤无副作用。
具体实施方式
为使本发明实施例的目的、技术方案和优点更加清楚,下面将结合本发明实施例,对本发明实施例中的技术方案进行清楚、完整地描述,显然,所描述的实施例是本发明一部分实施例,而不是全部的实施例。基于本发明中的实施例,本领域普通技术人员在没有作出创造性劳动前提下所获得的所有其他实施例,都属于本发明保护的范围。
实施例1:
一种治疗皮肤病的中药组合物,该中药组合物原料包括以下重量份的组分:黄芩5份、丹参5份、白藓皮8份、川牛膝4份、莪术6 份、银花6份、木香4份、知母4份、雄黄4份、冰片份、医用石粉 10份。
上述中药组合物的制备方法为:
(1)按上述中药组合物的配方称取原料,将黄芩、丹参、白藓皮、川牛膝、莪术、银花、木香、知母切碎后混合得混合料A;
(2)将步骤(1)中混合料A放入砂锅中,冷水浸泡24小时;
(3)将步骤(2)中砂锅放置在小火上煮沸3小时,再加适量水煎煮3小时,将药渣过滤去除,得到药液A;将药渣挤压后得到的药液和药液A混合得到药液B;
(4)将步骤(3)得到的药液B静置12小时,静置沉淀后取上清液A;
(5)将步骤(4)得到的上清液A加热至沸,撇去浮沫,小火煎煮浓缩,得到稠膏状物A;
(6)向步骤(5)中得到的稠膏状物A中添加雄黄、冰片和医药石粉混合均匀得到混合料B;
(7)将凡士林熔化后,灭菌冷却,将羊毛脂灭菌,将液体石蜡灭菌,将凡士林、羊毛脂和液体石蜡混合得混合料C;
(8)将步骤(6)中得到的混合料B和步骤(7)中得到的混合料C混合得到软膏,所得软膏即为本发明中药组成物。
实施例2:
一种治疗皮肤病的中药组合物,该中药组合物原料包括以下重量份的组分:黄芩10份、丹参10份、白藓皮12份、川牛膝8份、莪术 14份、银花14份、木香12份、知母12份、雄黄12份、冰片14份、医用石粉16份。
上述中药组合物的制备方法同实施例1。
实施例3:
一种治疗皮肤病的中药组合物,该中药组合物包括如下重量份的组分:黄芩6份、丹参6份、白藓皮9份、川牛膝4份、莪术8份、银花8份、木香5份、知母5份、雄黄5份、冰片8份、医用石粉12 份;
上述中药组合物的制备方法同实施例1。
实施例4:
一种治疗皮肤病的中药组合物,该中药组合物包括如下重量份的组分:黄芩9份、丹参9份、白藓皮11份、川牛膝6份、莪术12份、银花12份、木香7份、知母7份、雄黄7份、冰片12份、医用石粉 14份;
上述中药组合物的制备方法同实施例1。
实施例5:
一种治疗皮肤病的中药组合物,该中药组合物包括如下重量份的组分:黄芩7份、丹参7份、白藓皮9份、川牛膝5份、莪术10份、银花10份、木香6份、知母6份、雄黄6份、冰片10份、医用石粉 13份。
中药组合物的制备方法同实施例1。
对比例1:
本对比例与实施例5对比,该中药组合物未设置黄芩,其他含量和制备步骤与实施例5一致。
对比例2:
本对比例与实施例5对比,该中药组合物未设置知母,其他含量和制备步骤与实施例5一致。
实验验证
为了证明本发明治疗皮肤病的中药组合药的治疗效果,临床收集牛皮癣、乳腺炎、臁疮腿、痤疮、湿疹、疥疮、毒疮皮肤病的患者210 例,其中男性患者105例,女性患者105例,年龄20-50岁;其中牛皮癣、乳腺炎、臁疮腿、痤疮、湿疹、疥疮、毒疮皮肤病病例各30例。
使用方法:按照实施例5和对比例1-2的配方及方法制备中药组合药,将药品涂擦于洗净的患处,每日用药2-3次,共敷涂30日。具体参见下表:
牛皮癣 | 乳腺炎 | 臁疮腿 | 痤疮 | 湿疹 | 疥疮 | 毒疮皮肤病 | |
实施例5 | 9 | 9 | 9 | 7 | 8 | 9 | 9 |
对比例1 | 7 | 8 | 6 | 8 | 7 | 7 | 6 |
对比例2 | 8 | 9 | 7 | 5 | 8 | 7 | 8 |
由上表可看出,本发明实施例5制备的中药组成物具有疗效显著、复发情况少、使用方便以及减少相关感染的优点。
以上实施例仅用以说明本发明的技术方案,而非对其限制;尽管参照前述实施例对本发明进行了详细的说明,本领域的普通技术人员应当理解:其依然可以对前述各实施例所记载的技术方案进行修改,或者对其中部分技术特征进行等同替换;而这些修改或者替换,并不使相应技术方案的本质脱离本发明各实施例技术方案的精神和范围。
Claims (8)
1.一种治疗皮肤病的中药组合物,其特征在于,该中药组合物包括如下重量份的组分:黄芩5-10份、丹参5-10份、白藓皮8-12份、川牛膝4-8份、莪术6-14份、银花6-14份、木香4-12份、知母4-12份、雄黄4-12份、冰片6-14份、医用石粉10-16份。
2.如权利要求1所述的中药组合物,其特征在于,该中药组合物包括如下重量份的组分:黄芩6-9份、丹参6-9份、白藓皮9-11份、川牛膝4-6份、莪术8-12份、银花8-12份、木香5-7份、知母5-7份、雄黄5-7份、冰片8-12份、医用石粉12-14份。
3.如权利要求2所述的中药组合物,其特征在于,该中药组合物包括如下重量份的组分:黄芩7份、丹参7份、白藓皮9份、川牛膝5份、莪术10份、银花10份、木香6份、知母6份、雄黄6份、冰片10份、医用石粉13份。
4.根据权利要求1-3任一项所述的中药组合物,其特征在于,所述中药组合物为软膏剂,还含有如下重量份数的成分:凡士林40-60份、液体石蜡4-6份、羊毛脂4-6份。
5.如权利要求4任一项所述的中药组合物,其特征在于,所述中药组合物的制作方法为:
(1)按上述中药组合物的配方称取原料,将黄芩、丹参、白藓皮、川牛膝、莪术、银花、木香、知母切碎后混合得混合料A;
(2)将步骤(1)中混合料A放入砂锅中,冷水浸泡18-24小时;
(3)将步骤(2)中砂锅放置在小火上煮沸3小时,再加适量水煎煮3小时,将药渣过滤去除,得到药液A;将药渣挤压后得到的药液和药液A混合得到药液B;
(4)将步骤(3)得到的药液B静置10-12小时,静置沉淀后取上清液A;
(5)将步骤(4)得到的上清液A加热至沸,撇去浮沫,小火煎煮浓缩,得到稠膏状物A;
(6)向步骤(5)中得到的稠膏状物A中添加雄黄、冰片和医药石粉混合均匀得到混合料B;
(7)将凡士林熔化后,灭菌冷却,将羊毛脂灭菌,将液体石蜡灭菌,将凡士林、羊毛脂和液体石蜡混合得混合料C;
(8)将步骤(6)中得到的混合料B和步骤(7)中得到的混合料C混合得到软膏,所得软膏即为本发明中药组成物。
6.如权利要求1-3中任一所述所述的中药组合物,其特征在于,所述雄黄研细过100-120目筛、冰片研细过200-230目筛、医用石粉研细过100-120目筛。
7.如权利要求5所述的中药组合物,其特征在于,所述步骤(2)中冷水没过药材15-20厘米。
8.如权利要求5所述的中药组合物,其特征在于,所述步骤(4)中所得上清液A过100-120目筛。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010585567.5A CN111617212A (zh) | 2020-06-23 | 2020-06-23 | 一种治疗皮肤病的中药组合物 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010585567.5A CN111617212A (zh) | 2020-06-23 | 2020-06-23 | 一种治疗皮肤病的中药组合物 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN111617212A true CN111617212A (zh) | 2020-09-04 |
Family
ID=72267652
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202010585567.5A Pending CN111617212A (zh) | 2020-06-23 | 2020-06-23 | 一种治疗皮肤病的中药组合物 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN111617212A (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113398226A (zh) * | 2021-08-06 | 2021-09-17 | 颐康医药科技(天津)有限公司 | 一种治疗皮肤病的中药组合物的临床使用方法 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103768497A (zh) * | 2012-10-24 | 2014-05-07 | 海南碧凯药业有限公司 | 一种药物组合物及其制剂和用途 |
-
2020
- 2020-06-23 CN CN202010585567.5A patent/CN111617212A/zh active Pending
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103768497A (zh) * | 2012-10-24 | 2014-05-07 | 海南碧凯药业有限公司 | 一种药物组合物及其制剂和用途 |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113398226A (zh) * | 2021-08-06 | 2021-09-17 | 颐康医药科技(天津)有限公司 | 一种治疗皮肤病的中药组合物的临床使用方法 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN106075120B (zh) | 一种湿疹乳膏剂 | |
CN114272339B (zh) | 一种治疗湿疹、皮肤过敏或银屑病的中药组合物及其制备方法 | |
Coopoosamy et al. | Traditional use, antibacterial activity and antifungal activity of crude extract of Aloe excelsa | |
CN111870568B (zh) | 一种抗敏止痒植物组合物及其制备方法与用途 | |
CN109364207A (zh) | 一种治疗和缓解痤疮的组合物及制备方法与应用 | |
CN103656369A (zh) | 一种防治银屑病复方药 | |
CN108785580A (zh) | 24h+抗菌液及其制备方法 | |
CN111617212A (zh) | 一种治疗皮肤病的中药组合物 | |
CN109303743B (zh) | 中药组合物在制备护肤品中的应用 | |
CN105395593A (zh) | 一种含有艾叶提取物的止痒药膏及其制备方法 | |
CN109549958B (zh) | 治疗激素依赖性皮炎的组合物及其制备方法 | |
CN107890486B (zh) | 一种中药外用消炎制剂及其制备方法和应用 | |
CN106963912B (zh) | 一种治疗湿疹的降香复方组合物及其制备方法 | |
CN106822321B (zh) | 伤科黄水在制备治疗毛周角化症的药物中的应用 | |
CN109260355A (zh) | 一种治疗和改善银屑病的组合物和制备方法与应用 | |
CN101391065A (zh) | 一种用于治疗急慢性盆腔炎的复方木鳖子花椒汤 | |
CN105770656B (zh) | 一种治疗皮肤瘙痒的中药散剂及其应用 | |
CN104888056B (zh) | 一种外用消炎、护理组合物产品及其制备工艺 | |
CN108785212B (zh) | 一种具有抑菌和抗螨的中药复合物及其应用 | |
CN113713018A (zh) | 一种湿疹膏的中药组合物及其制作工艺 | |
CN113181318A (zh) | 一种治疗痔疮的中药药膏及其制备方法 | |
CN112294929A (zh) | 一种妇科中药盐洗液及其制备方法和应用 | |
CN101953951B (zh) | 一种手足保健美容液及其制备方法 | |
CN105031596A (zh) | 一种治疗钱币状湿疹的软膏及其制备方法 | |
CN112022947A (zh) | 基于传统中草药及小分子化合物的抑菌剂及其制备方法和应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20200904 |
|
WD01 | Invention patent application deemed withdrawn after publication |